Who founded Rondo Therapeutics?

Rondo Therapeutics was founded by Shelley Force Aldred, Nathan Trinklein in 2021.

Who are Rondo Therapeutics's investors?

Rondo Therapeutics's investors include SV Health Investors, Canaan Partners, Johnson & Johnson Innovation – JJDC, Novo Holdings.

How much funding has Rondo Therapeutics raised?

Rondo Therapeutics has disclosed $67M raised across 1 round.

Rondo Therapeutics

Founded 2021 · 29 employees on LinkedIn · 4 known investors

Find your way into Rondo Therapeutics

807 people in our graph share verified history with the Rondo Therapeutics team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Nathan Trinklein · together at Stanford University (overlapped)

×8knows the team · via Stanford University

×3knows the team · via Stanford University School of Medicine

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue. Its therapies aim to expand the therapeutic window for eradicating tumors.

Biotech Healthtech

Founders & leadership

Rondo Therapeutics was founded in 2021 by Shelley Force Aldred and Nathan Trinklein.

Shelley Force Aldred inCo-Founder & Chief Executive OfficerShelley Force Aldred earned a Ph.D. in Genetics from Stanford University and has co-founded multiple biopharmaceutical companies; she currently leads Rondo Therapeutics as CEO, guiding the company through early clinical development of bispecific antibody therapeutics for oncology.

Nathan Trinklein inCo-Founder, President & CSONathan Trinklein holds a Ph.D. from Stanford University and has founded multiple biotech companies. He is co-founder, president, and chief scientific officer of Rondo Therapeutics, which develops bispecific and multispecific antibody therapeutics for immuno-oncology.

KatherineChief Development Officer

ThomasChief Medical Officer

Investors · 4

SV Health InvestorsBoston · $1M – $20M

Canaan PartnersreportedStamford · $500K – $20M

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

Novo HoldingsreportedCopenhagen · $1.1M – $54M

Funding

SEC filings, press & company announcements

$67M disclosed across 1 round · 2022

$67MSeries AMar 2022 · 2 sources
Canaan Partners (lead), Red Tree Venture Capital (lead), Johnson & Johnson Innovation – JJDC, Inc., Novo Holdings A/S, SV Health Investors
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs - MedCity Newsmedcitynews.com · Mar 2022

Rondo Therapeutics locks in $67m Series Aventurecapitaljournal.com · Mar 2022

Vesalius, Rondo Debut to Redefine Treatment Paradigms - BioSpacebiospace.com · Mar 2022

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumorsprnewswire.com · Mar 2022

Operations Manager in Fremont at Rondo Therapeutics | Apply now! – StudySmarter – Talentstalents.vaia.com

Frequently asked questions

What does Rondo Therapeutics do?: Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue. Its therapies aim to expand the therapeutic window for eradicating tumors.
Who founded Rondo Therapeutics?: Rondo Therapeutics was founded by Shelley Force Aldred, Nathan Trinklein in 2021.
Who are Rondo Therapeutics's investors?: Rondo Therapeutics's investors include SV Health Investors, Canaan Partners, Johnson & Johnson Innovation – JJDC, Novo Holdings.
How much funding has Rondo Therapeutics raised?: Rondo Therapeutics has disclosed $67M raised across 1 round.